Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 3,600 shares of the firm’s stock in a transaction that occurred on Monday, November 21st. The stock was bought at an average price of $10.41 per share, for a total transaction of $37,476.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $31,947,779.91. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Tuesday, November 22nd, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was bought at an average price of $10.28 per share, for a total transaction of $55,512.00.
  • On Friday, November 18th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The stock was bought at an average price of $10.38 per share, for a total transaction of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock. The stock was bought at an average price of $10.13 per share, for a total transaction of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost bought 14,600 shares of Opko Health stock. The stock was bought at an average price of $9.46 per share, for a total transaction of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The stock was bought at an average price of $9.33 per share, for a total transaction of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The stock was bought at an average price of $9.22 per share, for a total transaction of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The stock was bought at an average price of $9.48 per share, for a total transaction of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.49 per share, for a total transaction of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost purchased 11,800 shares of Opko Health stock. The shares were acquired at an average price of $9.43 per share, for a total transaction of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.46 per share, for a total transaction of $94,600.00.

Opko Health Inc. (NASDAQ:OPK) opened at 10.70 on Thursday. The company’s 50 day moving average price is $9.76 and its 200 day moving average price is $9.87. The firm’s market cap is $5.97 billion. Opko Health Inc. has a 52-week low of $7.12 and a 52-week high of $11.85.

Opko Health (NASDAQ:OPK) last released its earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The firm earned $298 million during the quarter, compared to analysts’ expectations of $322 million. Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. The company’s revenue was up 108.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 EPS. Analysts predict that Opko Health Inc. will post ($0.08) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

OPK has been the subject of a number of research reports. TheStreet cut Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. Zacks Investment Research raised Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Jefferies Group reissued a “hold” rating and set a $10.00 price objective on shares of Opko Health in a research report on Monday, October 10th. Finally, JPMorgan Chase & Co. set a $14.00 price target on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. Opko Health currently has a consensus rating of “Hold” and a consensus target price of $13.17.

Institutional investors have recently added to or reduced their stakes in the company. Whalerock Point Partners LLC purchased a new position in Opko Health during the third quarter worth about $2,100,000. Piedmont Investment Advisors LLC purchased a new position in Opko Health during the third quarter worth about $622,000. Price T Rowe Associates Inc. MD boosted its position in Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock worth $10,038,000 after buying an additional 28,700 shares during the period. Finally, LPL Financial LLC boosted its position in Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock worth $142,000 after buying an additional 504 shares during the period. Hedge funds and other institutional investors own 20.33% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Phillip Md Et Al Frost Acquires 3,600 Shares of Opko Health Inc. (OPK) Stock” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/24/phillip-md-et-al-frost-acquires-3600-shares-of-opko-health-inc-opk-stock.html.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.